Securities Litigation: Pacira Pharmaceuticals Investors Encouraged to Explore Legal Options
Investors who have suffered losses as a result of their investment in Pacira Pharmaceuticals (NASDAQ: PCRX) are encouraged to contact securities litigation law firm Faruqi & Faruqi, LLP for a consultation, following the announcement of a securities class action lawsuit against the company. The lawsuit alleges that Pacira and certain of its executives made false and misleading statements regarding the effectiveness of its EXPAREL product.
Background on the Lawsuit
The lawsuit, filed in the United States District Court for the Eastern District of New York, alleges that Pacira and certain of its executives made false and misleading statements regarding the effectiveness and safety of its EXPAREL product, an extended-release local anesthetic used during surgical procedures. The complaint alleges that these statements were made between February 25, 2020, and November 11, 2020.
The alleged false statements came to light on November 11, 2020, when the U.S. Food and Drug Administration (FDA) issued a warning letter to Pacira regarding the safety of EXPAREL. The FDA stated that the company had failed to address safety concerns related to the product, including reports of serious adverse events, such as respiratory failure and cardiac arrest.
Impact on Investors
Following the FDA warning, Pacira’s stock price dropped significantly, causing losses for many investors. Those who purchased Pacira securities between February 25, 2020, and November 11, 2020, may be eligible to recover their losses through the securities class action lawsuit. It is important for investors to act quickly and contact a securities litigation law firm, such as Faruqi & Faruqi, LLP, to discuss their options.
Impact on the World
The Pacira Pharmaceuticals case highlights the importance of transparency and safety in the pharmaceutical industry. The FDA’s warning letter serves as a reminder that companies must take seriously their responsibility to report safety concerns related to their products. Failure to do so can result in significant consequences, including financial losses for investors and potential harm to patients.
Additionally, securities class action lawsuits like the one against Pacira serve an important role in holding companies accountable for making false and misleading statements. These lawsuits provide a means for investors to recover their losses and seek justice. They also serve as a deterrent for companies to engage in fraudulent behavior.
Contacting Faruqi & Faruqi, LLP
If you invested in Pacira Pharmaceuticals between February 25, 2020, and November 11, 2020, and suffered losses as a result, you may be eligible to recover your losses. Contact securities litigation law firm Faruqi & Faruqi, LLP directly to discuss your options. You can reach the firm at (877) 247-4292 or (212) 983-9330. The consultation is free of charge.
- Faruqi & Faruqi, LLP: (877) 247-4292 or (212) 983-9330
Don’t wait, contact Faruqi & Faruqi, LLP today to discuss your potential case.
Conclusion
The Pacira Pharmaceuticals case serves as a reminder of the importance of transparency and safety in the pharmaceutical industry and the role of securities class action lawsuits in holding companies accountable for making false and misleading statements. If you invested in Pacira between February 25, 2020, and November 11, 2020, and suffered losses as a result, contact Faruqi & Faruqi, LLP directly to discuss your options. The consultation is free of charge.
At Faruqi & Faruqi, LLP, we are committed to helping investors recover their losses and seek justice. Contact us today to discuss your potential case.
